Evidence map›Paper›PMID 24865558›Full record

ArticlemBio2014

Enhanced specialized transduction using recombineering in Mycobacterium tuberculosis.

JoAnn M Tufariello, Adel A Malek, Catherine Vilchèze, Laura E Cole, Hannah K Ratner, Pablo A González, Paras Jain, Graham F Hatfull, Michelle H Larsen, William R Jacobs

Open access · goldAbstract read
In one paragraph

Article in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Construction and characterization of novelInfection and immunity · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Frontiers in immunology · 2022
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

JoAnn M Tufariello
Adel A MalekDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Catherine Vilchèze
Laura E ColeDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Hannah K RatnerDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Pablo A GonzálezDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, New York, USA.
Paras Jain
Graham F HatfullDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Michelle H Larsen
William R Jacobsjacobsw@hhmi.org.
Albert Einstein College of Medicine · USHoward Hughes Medical Institute · USUniversity of Pittsburgh · US

Funding

Immunology/Pathology CoreP30AI051519 · NIAID · YESHIVA UNIVERSITY · PI GOLDSTEIN, HARRIS · 2003 to 2013
$18.6M
"The Tuberculous Granuloma"P01AI063537 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI CHAN, JOHN R. · 2005 to 2015
$15.7M
Molecular Genetic Analysis of Mycobacterium TuberculosisR37AI026170 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI WILLIAM Robert JACOBS · 2004 to 2026
$7.7M
MOLECULAR GENETIC ANALYSIS OF MYCOBACTERIUM TUBERCULOSISR01AI026170 · NIAID · YESHIVA UNIVERSITY · PI JACOBS, WILLIAM ROBERT · 1989 to 2022
$7.1M
Vaccines for Extensively Drug Resistant TuberculosisR01AI098925 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JACOBS, WILLIAM ROBERT · 2012 to 2016
$5.8M
High throughput Genetic Analysis of Mycobacterium tuberculosisRC4AI092760 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI JACOBS, WILLIAM ROBERT · 2010 to 2010
$4.0M
MOLECULAR GENETIC ANALYSIS OF MYCOBACTERIUM TUBERCULOSISR22AI026170 · NIAID · YESHIVA UNIVERSITY · PI JACOBS, WILLIAM ROBERT · 1989 to 1991
–
NIAID NIH HHS AI0-51519NIAID NIH HHS AI26170NIAID NIH HHS AI92760NIAID NIH HHS P01 AI063537NIAID NIH HHS P30 AI051519NIAID NIH HHS R01 AI026170NIAID NIH HHS R01 AI098925NIAID NIH HHS R37 AI026170NIAID NIH HHS RC4 AI092760
6 · The paper itself

Abstract

unlabelledG: enetic engineering has contributed greatly to our understanding of Mycobacterium tuberculosis biology and has facilitated antimycobacterial and vaccine development. However, methods to generate M. tuberculosis deletion mutants remain labor-intensive and relatively inefficient. Here, methods are described that significantly enhance the efficiency (greater than 100-fold) of recovering deletion mutants by the expression of mycobacteriophage recombineering functions during the course of infection with specialized transducing phages delivering allelic exchange substrates. This system has been successfully applied to the CDC1551 strain of M. tuberculosis, as well as to a ΔrecD mutant generated in the CDC1551 parental strain. The latter studies were undertaken as there were precedents in both the Escherichia coli literature and mycobacterial literature for enhancement of homologous recombination in strains lacking RecD. In combination, these measures yielded a dramatic increase in the recovery of deletion mutants and are expected to facilitate construction of a comprehensive library of mutants with every nonessential gene of M. tuberculosis deleted. The findings also open up the potential for sophisticated genetic screens, such as synthetic lethal analyses, which have so far not been feasible for the slow-growing mycobacteria. IMPORTANCE: Genetic manipulation of M. tuberculosis is hampered by laborious and relatively inefficient methods for generating deletion mutant strains. The combined use of phage-based transduction and recombineering methods greatly enhances the efficiency by which knockout strains can be generated. The additional elimination of recD further enhances this efficiency. The methods described herein will facilitate the construction of comprehensive gene knockout libraries and expedite the isolation of previously difficult to recover mutants, promoting antimicrobial and vaccine development.

Indexed as

Genetic EngineeringTransduction, GeneticAllelesGene Expression Regulation, BacterialGenetic LociMutationMycobacteriophagesMycobacterium tuberculosisPlasmidsRecombination, Genetic

Identifiers

PMID24865558
PMCPMC4045075
OpenAlexW2141133955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.